TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17545701
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (sd-NVP) prophylaxis
Study: 11212969
Drug: Cortisol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 80 mg/day + L-arginine 21 g/day
Study: 11212969
Drug: Cortisol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 80 mg/day + Placebo
Study: 7753427
Drug: Nicardipine (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (80-120 mg daily)
Study: 7753427
Drug: Nifedipine (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40-60 mg daily)
Study: 3058537
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 mg orally at night)
Study: 18854803
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 (Dicoflor Elle, Dicofarm, Roma, Italy) administered orally, two tablets daily for 15 days
Study: 18854803
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy followed by Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Study: 10937511
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (30 microg/ml zinc)
Study: 10937511
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (80 microg/ml zinc)
Study: 8765253
Drug: Subcutaneous closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous closed drainage system
Study: 8765253
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous closed drainage system
Study: 8765253
Drug: Subcutaneous closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous closed drainage system with prophylactic antibiotics
Study: 8765253
Drug: No subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subcutaneous closed drainage system without prophylactic antibiotics
Study: 1576070
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled via Turbohaler (TBH) at varying inspiratory flows (34 to 88 l min‐1)
Study: 1576070
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled via Turbohaler (TBH) with prior exhalation through the device
Study: 1576070
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled via Turbohaler (TBH) at approximately 34 l min‐1
Study: 27339736
Drug: BAY 81-8973
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 81-8973 prophylaxis (twice-weekly vs. three times-weekly dosing)
Study: 25048508
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tramadol 100 mg in 500 mL 0.9%NaCl one hour before the procedure
Study: 25048508
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL 0.9%NaCl (control group)
Study: 25048508
Drug: Postoperative analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesia (diclofenac 75 mg i.m.) when required
Study: 22158143
Drug: Vibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration treatment at 25 Hz, 35 Hz, and 45 Hz with low amplitude (1 mm) and high amplitude (3.1 mm)
Study: 22158143
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a soft pad during vibration treatment
Study: 22158143
Drug: Vibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration treatment (various frequencies and amplitudes)
Study: 18041883
Drug: Posaconazole 200
Normalized name: posaconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 200 mg oral suspension 3 times/day for a maximum of 16 weeks
Study: 11028251
Drug: Heparin i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin i.v. bolus
Study: 11028251
Drug: Pilot study
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot study of bolus dosing
Study: 29376858
Drug: Exercise Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise Training (ET), 90 minutes of aerobic and strength training, 72 treatment sessions over 6 months
Study: 29376858
Drug: Cognitive Treatment
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Treatment (CT), 90 minutes of cognitive stimuli
Study: 26162946
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with rosuvastatin (5 mg for 4 weeks, then 10 mg for 8 weeks)
Study: 26162946
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy with rosuvastatin (2.5 mg for 12 weeks)
Study: 18617126
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (TFP) - Duragesic 50 microg/h, applied approximately 10 hours before induction of general anesthesia
Study: 15975304
Drug: Breviscapine intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breviscapine intravenously dripped for 2 treatment courses
Study: 16021880
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of didanosine plus stavudine plus nevirapine with hydroxyurea
Study: 16021880
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of didanosine plus stavudine plus nevirapine without hydroxyurea
Study: 20427778
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (800 IU daily)
Study: 12242596
Drug: Fluoxetine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine as the experimental drug
Study: 12242596
Drug: Fluoxetine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine as the control drug
Study: 9819017
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg (with HCTZ 12.5 mg increased to 25 mg)
Study: 9819017
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg (increased to 60 mg and 90 mg)
Study: 2547410
Drug: Fluconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (50 mg daily for 21-28 days)
Study: 2547410
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before fluconazole therapy)
Study: 21695251
Drug: Replication-defective Ad5
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replication-defective Ad5 gag/pol/nef vaccine
Study: 19229545
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation the day before the operation (n = 41)
Study: 12547889
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (0.1 units/kg body wt)
Study: 12547889
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.1 units/kg body wt)
Study: 4025217
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of Ba-wei-wan
Study: 24843973
Drug: Combination electroacupuncture
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination electroacupuncture anesthesia (group B)
Study: 22640930
Drug: 2.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/d n-3 PUFAs
Study: 22640930
Drug: 1.25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g/d n-3 PUFAs
Study: 18235121
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (400 mg/d and 600 mg/d)
Study: 15783259
Drug: Proven effective
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proven effective therapy
Study: 12020263
Drug: Budipine 20
Normalized name: budipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budipine 20 mg, 3 times daily
Study: 7883776
Drug: Mesna administration
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna administration (Arm A: i.v. in equal doses 15 min before and 4 h and 8 h after ifosfamide; Arm B: three equivalent doses 15 min before (i.v.) and 4 h (i.v.) and 8 h (p.o., double dose); Arm C: i.v. in two equal doses 15 min before and 4 h after).
Study: 43585
Drug: methyl-salazosulphapyridine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl-salazosulphapyridine (125 mg x 3 daily)
Study: 43585
Drug: salazosulphapyridine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: salazosulphapyridine (1 g x 3 daily)
Study: 24028354
Drug: Medication reviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reviews performed by a physician
Study: 12779351
Drug: Nephrectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nephrectomy followed by treatment with interferon alfa‐2b
Study: 12779351
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with interferon alfa‐2b alone
Study: 4027102
Drug: MST Continus
Normalized name: MST Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST Continus 20 mg (oral morphine)
Study: 29546298
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L semiskimmed milk/wk
Study: 29546298
Drug: Usual milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual milk consumption (baseline median: 140 mL/d; IQR: 40‐240 mL/d)
Study: 26893546
Drug: Multimatrix mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimatrix mesalamine 30 mg/kg/day
Study: 26893546
Drug: Multimatrix mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimatrix mesalamine 60 mg/kg/day
Study: 26893546
Drug: Multimatrix mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimatrix mesalamine 100 mg/kg/day
Study: 26893546
Drug: Multimatrix mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimatrix mesalamine (all doses)
Study: 20610636
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (serum 25(OH)D concentration < 30 ng/mL)
Study: 18331221
Drug: 10% water
Normalized name: amino acids 8 % in dextrose 10% water 8 %-10 % INTRAVEN INTRAVENOUS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% water solution of sucrose (CHO; 4 kcal/kg body mass)
Study: 15980352
Drug: 873140 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 873140 50 mg to 800 mg single dose
Study: 15980352
Drug: 873140 200
Normalized name: dimethicone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 873140 200 mg to 800 mg repeat dose (BID for 8 days)
Study: 15980352
Drug: Food consumption
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food consumption with 400 mg dose
Study: 15980352
Drug: 873140 200
Normalized name: dimethicone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 873140 200 mg BID
Study: 15980352
Drug: 873140 800
Normalized name: Peptimax 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 873140 800 mg BID
Study: 3291223
Drug: Cs monotherapy
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cs monotherapy (8 to 10 mg/kg/d)
Study: 3291223
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Cs, azathioprine, and prednisolone or Cs and azathioprine)
Study: 766879
Drug: Wistar RA
Normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wistar RA 27/3 vaccine
Study: 766879
Drug: Cendehill strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cendehill strain live attenuated vaccine
Study: 23932803
Drug: Other cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other cholesterol-lowering medications
Study: 23932803
Drug: No cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cholesterol-lowering agents (Control group)
Study: 18155058
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 mg/kg bolus dose)
Study: 18155058
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (5 mcg/mL)
Study: 20617345
Drug: Hospital-prepared supplements
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-prepared supplements
Study: 20617345
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available supplements
Study: 20617345
Drug: Hospital supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital supplements
Study: 12002666
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of latanoprost 0.005% and timolol 0.5%
Study: 8071762
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G
Study: 8071762
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G
Study: 2847079
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg IM daily of purified bovine brain gangliosides (Cronassial)
Study: 2847079
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IM daily of purified bovine brain gangliosides (Cronassial)
Study: 24927471
Drug: Internet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet treatment (NET)
Study: 22616078
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 2 weeks and intranasal budesonide for 12 weeks
Study: 17852670
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high molecular weight glucose polymer solution
Study: 17852670
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight glucose polymer solution
Study: 11788414
Drug: Diuretic (spironolactone:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (spironolactone: 100 mg/day, 3 days)
Study: 10412846
Drug: Original plaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original plaque index derived from buccal surfaces of all teeth
Study: 2110425
Drug: Midazolam (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.16 mg/kg) with flumazenil (0.55 mg)
Study: 2110425
Drug: Propofol (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.50 mg/kg)
Study: 2110425
Drug: Midazolam (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.16 mg/kg)
Study: 383023
Drug: Naloxone IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone IV (0.01 mg/kg)
Study: 383023
Drug: Naloxone IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone IV (0.02 mg/kg)
Study: 3109893
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antagonist)
Study: 21551966
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node biopsy using dual-agent injection of blue dye and radioactive colloid
Study: 17442659
Drug: Ibandronate 50
Normalized name: ibandronic acid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 50 mg/day
Study: 17442659
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg every 4 weeks
Study: 14696020
Drug: Olopatadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine (10 mg)
Study: 14696020
Drug: d-chlorpheniramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-chlorpheniramine (4 mg)
Study: 8639180
Drug: IL-10 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 and IL-4 (combination)
Study: 1600042
Drug: Cisapride 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 2.5 mg three times daily for 7 days
Study: 1600042
Drug: Cisapride 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 2.5 mg plus Domperidone 10 mg three times daily for 7 days
Study: 29428919
Drug: Kangaroo mother
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo mother care with Music therapy
Study: 24658964
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/day (IM400)
Study: 24658964
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg/day (IM800)
Study: 20075953
Drug: Novel vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel vaccine adjuvant system
Study: 20075953
Drug: Standard HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HBV vaccine
Study: 17914132
Drug: Proprietary formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprietary formulation of Camellia sinensis (green tea) capsules, twice a day for 3 months
Study: 17914132
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, twice a day for 3 months
Study: 9831059
Drug: Aceclofenac 150
Normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac 150 mg
Study: 7924164
Drug: acute hyperinsulinaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Study: 7924164
Drug: prolonged hyperinsulinaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: prolonged hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Study: 7924164
Drug: euglycaemia (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: euglycaemia (4.5 mmol/l)
Study: 54631
Drug: Influenza-B vaccine
Normalized name: influenza B virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza-B vaccine
Study: 54631
Drug: Influenza-A vaccine
Normalized name: influenza A virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza-A vaccine (A/Hong Kong)
Study: 54631
Drug: Influenza-B H.I.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza-B H.I. antibody
Study: 31779179
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and calcium fortified yogurt (400 IU of vitamin D3 and 800 mg calcium daily for 3 months)
Study: 31779179
Drug: Non-fortified yogurt
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fortified yogurt (300 mg calcium, no vitamin D3)
Study: 27670603
Drug: Amoxicillin group
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin group
Study: 19349548
Drug: Dose-intensified regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensified regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 30 weeks
Study: 17764540
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg once-daily
Study: 17764540
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg once-daily
Study: 17764540
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Dabigatran 220 mg, Dabigatran 150 mg, Enoxaparin)
Study: 15139393
Drug: Pork meat
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork meat diet (170 g pig meat/10 MJ per day, 106 +/- 13 microg Se/d)
Study: 9919621
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid supplementation at 0-100 mg/day for 14 weeks
Study: 7750677
Drug: Mannitol group
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol group (n = 20) treated by whole gut irrigation with a 5 L solution containing 40 g/L of mannitol
Study: 3281488
Drug: C25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: C25 (25 mg/kg chloroquine over 3 days)
Study: 3281488
Drug: C50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: C50 (50 mg/kg chloroquine over 5 days)
Study: 1363409
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of hydrocortisone succinate, 100 mg bolus at time 0 followed by 250 mg in 250 ml saline for 120 min
Study: 1363409
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of saline, 250 ml
Study: 408839
Drug: l-tryptophane 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tryptophane 1 g
Study: 408839
Drug: l-tryptophane 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tryptophane 3 g
Study: 27085364
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP therapy combined with a rehabilitation programme
Study: 21966999
Drug: Darbepoetin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoetin (300 μg)